DOCU Stock Analysis: DocuSign | NASDAQ
Software - Application | NASDAQ, USA | Market Cap: 15.937m USD | 12M Return: 14.8% | US2561631068 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 189M
EPS Trend: 86.4%
Qual. Beats: -1
Rev. Trend: 100.0%
Qual. Beats: 9
Warnings
Tailwinds
Seasonality 8.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DocuSign, Inc. is a provider of electronic signature solutions serving customers in the United States and internationally. The companys core offering centers on an AI-powered Intelligent Agreement Management (IAM) platform that supports the full agreement lifecycle, including eSignature, Contract Lifecycle Management (CLM), and Document Generation. Beyond these core products, DocuSign provides a range of supplementary tools such as signer identification, standards-based digital certificates, analytics-based monitoring, remote online notarization, and web forms. It also offers tailored solutions for specific verticals, including real estate brokers, U.S. federal government agencies through FedRAMP authorization, and life sciences customers with compliance-focused modules. Products are distributed via direct sales, partner-assisted channels, and digital self-service purchasing.
DocuSign operates as a subscription-based software (SaaS) company within the Application Software sub-industry of the Information Technology sector, serving both enterprise and individual users. Founded in 2003 and headquartered in San Francisco, California, the company has been publicly traded on NASDAQ since its 2018 IPO.
- Subscription revenue growth and net retention rate trends
- Intelligent Agreement Management adoption lifts average contract value
- Adobe Sign competition pressures e-signature market share
| Net Income: 329.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.30 > 0.02 and ΔFCF/TA 6.56 > 1.0 |
| NWC/Revenue: -20.95% < 20% (prev -14.78%; Δ -6.17% < -1%) |
| CFO/TA 0.33 > 3% & CFO 1.32b > Net Income 329.9m |
| Net Debt (-594.6m) to EBITDA (565.0m): -1.05 < 3 |
| Current Ratio: 0.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.1m) vs 12m ago -8.85% < -2% |
| Gross Margin: 79.49% > 18% (prev 79.34%; Δ 0.15% > 0.5%) |
| Asset Turnover: 84.98% > 50% (prev 78.37%; Δ 6.61% > 0%) |
| Interest Coverage Ratio: 187.4 > 6 (EBIT TTM 442.2m / Interest Expense TTM 2.36m) |
| A: -0.18 (Total Current Assets 1.27b - Total Current Liabilities 1.97b) / Total Assets 3.96b |
| B: -0.59 (Retained Earnings -2.33b / Total Assets 3.96b) |
| C: 0.11 (EBIT TTM 442.2m / Avg Total Assets 3.96b) |
| D: 0.77 (Book Value of Equity 1.72b / Total Liabilities 2.24b) |
| Altman-Z'' = -1.52 = D |
| DSRI: 0.93 (Receivables 370.5m/366.8m, Revenue 3.36b/3.10b) |
| GMI: 1.00 (GM 79.34% / 79.49%) |
| AQI: 0.96 (AQ_t 0.53 / AQ_t-1 0.56) |
| SGI: 1.09 (Revenue 3.36b / 3.10b) |
| TATA: -0.25 (NI 329.9m - CFO 1.32b) / TA 3.96b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of October 31, 2026, the stock is trading at USD 82.17 with a total of 2,795,315 shares traded. Over the past week, the price has changed by -3.64%, over one month by +22.68%, over three months by +51.35% and over the past year by +14.75%.
Current recommended Stop Loss: 78.60 (which is 4.3% or 1.2 ATR below the current price).
DocuSign has received a consensus analysts rating of 3.25. Therefore, it is recommended to hold DOCU.
- StrongBuy: 2
- Buy: 2
- Hold: 15
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 70.4 | -14.4% |
P/E Trailing = 51.9939
P/E Forward = 12.0192
P/S = 4.7415
P/B = 5.7533
P/EG = 0.6465
Revenue TTM = 3.36b USD
EBIT TTM = 442.2m USD
EBITDA TTM = 565.0m USD
Long Term Debt = 167.6m USD (estimated: total debt 183.1m - short term 15.5m)
Short Term Debt = 15.5m USD (from shortTermDebt, last quarter)
Debt = 183.1m USD (from shortLongTermDebtTotal, last quarter) (leases 183.1m already included)
Net Debt = -594.6m USD (calculated: Debt 183.1m - CCE 777.7m)
Enterprise Value = 15.3b USD (15.9b + Debt 183.1m - CCE 777.7m)
Interest Coverage Ratio = 187.4 (Ebit TTM 442.2m / Interest Expense TTM 2.36m)
EV/FCF = 12.80x (Enterprise Value 15.3b / FCF TTM 1.20b)
FCF Yield = 7.81% (FCF TTM 1.20b / Enterprise Value 15.3b)
FCF Margin = 35.65% (FCF TTM 1.20b / Revenue TTM 3.36b)
Net Margin = 9.82% (Net Income TTM 329.9m / Revenue TTM 3.36b)
Gross Margin = 79.49% ((Revenue TTM 3.36b - Cost of Revenue TTM 689.5m) / Revenue TTM)
Gross Margin QoQ = 79.69% (prev 79.37%)
Tobins Q-Ratio = 3.87 (Enterprise Value 15.3b / Total Assets 3.96b)
Interest Expense / Debt = 1.29% (Interest Expense 2.36m / Debt 183.1m)
Taxrate = 24.98% (109.9m / 439.8m)
NOPAT = 331.7m (EBIT 442.2m * (1 - 24.98%))
Current Ratio = 0.64 (Total Current Assets 1.27b / Total Current Liabilities 1.97b)
Debt / Equity = 0.11 (Debt 183.1m / totalStockholderEquity, last quarter 1.72b)
Debt / EBITDA = -1.05 (Net Debt -594.6m / EBITDA 565.0m)
Debt / FCF = -0.50 (Net Debt -594.6m / FCF TTM 1.20b)
Total Stockholder Equity = 1.86b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.34% (Net Income 329.9m / Total Assets 3.96b)
RoE = 17.74% (Net Income TTM 329.9m / Total Stockholder Equity 1.86b)
RoCE = 21.81% (EBIT 442.2m / Capital Employed (Equity 1.86b + L.T.Debt 167.6m))
RoIC = 18.07% (NOPAT 331.7m / Invested Capital 1.84b)
WACC = 7.69% (E(15.9b)/V(16.1b) * Re(7.77%) + D(183.1m)/V(16.1b) * Rd(1.29%) * (1-Tc(0.25)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -69.66 | Cagr: -3.64%
[DCF] Terminal Value 77.97% ; FCFF base≈1.09b ; Y1≈1.25b ; Y5≈1.84b
[DCF] Fair Price = 151.7 (EV 27.8b - Net Debt -594.6m = Equity 28.4b / Shares 186.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 86.38 | EPS CAGR: 10.11% | SUE: -1.74 | # QB: -1
Revenue Correlation: 99.96 | Revenue CAGR: 8.13% | SUE: 1.86 | # QB: 9
EPS current Quarter (2026-10-31): EPS=1.18 | Chg30d=+0.00% | Revisions=+24% | Analysts=17
EPS current Year (2027-01-31): EPS=4.62 | Chg30d=+0.00% | Revisions=+86% | GrowthEPS=+20.3% | GrowthRev=+8.9%
EPS next Year (2028-01-31): EPS=5.21 | Chg30d=+0.12% | Revisions=+68% | GrowthEPS=+12.8% | GrowthRev=+8.0%
[Analyst] Revisions Ratio: +69% (up=45, down=7)